Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT02942407
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT02942407
-
- Other papers using this trial's data
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02942407. Randomized; no masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2019-07-27 (actual). Results posted on 2020-12-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
- Acronym
- RENAL-AF
- Condition
- Atrial Fibrillation
- Condition
- End Stage Renal Disease
- Intervention (Drug)
- apixaban
- Intervention (Drug)
- warfarin
- Lead sponsor
- Christopher Granger, MD
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct02942407- Content hash
a880027884e85cb74de564355d561188a5d2cefc2b2e5c277fdceecfdc1b566d